ClinicalTrials.Veeva

Menu

A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477

Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals

Status and phase

Completed
Phase 1

Conditions

Healthy Volunteers

Treatments

Drug: REGN2477
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT02870400
R2477-HV-1525

Details and patient eligibility

About

The primary objective of the study is to assess the safety and tolerability of single ascending doses of REGN2477 in healthy women not of childbearing potential.

Enrollment

41 patients

Sex

Female

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Healthy women not of childbearing potential between 18 and 65 years of age, with no significant health issues or clinically significant abnormal laboratory findings
  2. A body mass index (BMI) between 18 to 30 kg/m2, inclusive
  3. Provide a signed informed consent

Exclusion criteria

  1. Significant illness or history of significant illness
  2. Clinically significant abnormal CBC, clinical chemistry, and urine analysis at screening
  3. Current smoker or former smoker who has stopped smoking within 3 months prior to screening
  4. Positive urine drug test results during screening, or history of drug or alcohol abuse
  5. Donation or loss of, blood within 8 weeks prior to screening, or plasma up to 14 days prior to screening
  6. History of diabetes
  7. Abnormal blood pressure (BP)
  8. History of gynecological disorders or malignancies; history of breast malignancies; or history of benign gynecological or breast lesions that require medical treatment or follow up
  9. Reduced renal function
  10. Known history of chronic hepatitis or HIV
  11. Clinically significant ECG abnormalities
  12. Participation in any clinical research study within 30 days, or 5 halflives, of the study drug, whichever is greater, or for longer periods per regional requirements, prior to the screening visit
  13. Exposure to any biological drugs within 3 months of the screening visit (the name of the drug and duration of previous exposure will be recorded). Vaccination within 4 weeks of screening visit.
  14. History of hypersensitivity reactions to vaccines or other biologics
  15. History of hypersensitivity to doxycycline or other tetracycline antibiotics
  16. History of osteoporosis requiring osteoporosis treatments such as PTH, bisphosphonates, and denosumab
  17. Subject using hormone replacement therapy or thyroid replacement therapy will be excluded, unless they have been on stable doses of such therapy for at least 6 months and will remain on the same stable dose through the duration of the trial
  18. Use of systemic glucocorticoids, including oral glucocorticoids, for more than 10 days, within 3 months prior to screening.

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

41 participants in 2 patient groups

REGN2477
Experimental group
Description:
Cohorts 1 - 5 will receive REGN2477
Treatment:
Drug: REGN2477
Placebo
Experimental group
Description:
Cohorts 1 - 5 will receive placebo
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems